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Posttraumatic seizures (PTS) have been recognized as a major complication of traumatic 
brain injury (TBI). The annual incidence of TBI in the United States is 1.7 million. The role 
of anticonvulsants in the treatment of posttraumatic epilepsy (PTE) remains uncertain. 
Based on current studies, however, anticonvulsants have been shown to reduce early 
PTS occurring within the first 7 days, but little to no benefits have been shown in late PTS 
occurring after 7 days. In this paper, we provide a mini review of the role of anticonvul-
sants and current advances in the management of PTE.
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POSTTRAUMATiC ePiLePSY
Posttraumatic epilepsy (PTE) due to traumatic brain injury (TBI) has many causes, including war-
time combat, vehicle accidents, work-related injuries, and sports injuries. Wartime combat injuries, 
especially blast injuries and penetrating head injuries (PTI), have shown to increase the risk of 
seizures, as that of blast models of TBI (1–4). The annual incidence of TBI is estimated to be 1.7 
million in the United States, and seizures have been recognized as one of the major complications of 
this condition (5). The incidence of PTE was described by Annegers and colleagues who conducted 
a retrospective study in order to identify the characteristics of brain injuries that are associated 
with the development of seizures for 50 years. The results showed that the severity of the injury was 
correlated with the interval during which the risk of seizures was increased, even after more than 
20 years post injury (6). The other study of interest was the Vietnam Head Injury Study (VHIS) 
that was a prospective, longitudinal follow-up of 1,221 Vietnam War Veterans who had PTI. The 
prevalence of PTE in this cohort was 45–53%. Patients with PTI carry a high risk of PTE even for 
decades; so, long-term medical follow-up is required (7). Similarly, the prospective study by Salazar 
and colleagues showed that seizure frequency in the first year predicted future severity of seizures. 
A higher seizure frequency was seen in the first year and was also associated with subjects having a 
longer duration of epilepsy and persistent seizures (8).
ROLe OF AnTiCOnvULSAnTS in THe MAnAGeMenT OF 
POSTTRAUMATiC ePiLePSY
The seizures after head injury result in secondary brain damage, which involves increased intracranial 
pressure, increased metabolic brain demands post head injury, and excessive release of neurotransmitters, 
TABLe 1 | Summary of selected randomized controlled trials (RCT) for posttraumatic seizure prevention.
Reference Study design number of patients 
randomized (N)
Methods Outcome
Dikmen 
et al. (13)
RCT 124 Phenytoin versus placebo No significant differences seen in 
neuropsychological examinations in 1 year 
between the 2 groups
Patients were randomized to receive either PHT or placebo for 
1 year and observed one more year without medication
Temkin 
et al. (14)
RCT 123 Phenytoin versus placebo
Treatment was started within 24 h of injury for 1 year and then  
2 groups were followed for 2 years
Early seizures: improvement seen in the 
PHT GROUP
Late seizures: no difference between the  
2 groups
Young et al. 
(15)
RCT 244 Phenytoin versus placebo
Treatment was started within 24 h of injury
Early seizures: no difference between the  
2 groups
Late seizures: study was not designed to 
determine late seizure outcome
Young et al. 
(16)
RCT 179 Phenytoin versus placebo
Treatment was started within 24 h of injury and 2 groups were 
followed for 18 months to determine late seizure outcome
Early seizures: study was not designed to 
determine early seizure outcome
Late seizures: no difference between the  
2 groups
McQueen 
et al. (17)
RCT 164 Phenytoin versus placebo
Two groups were followed for 2 years
Occurrence of seizures was used as outcome measure
Early seizures: study was not designed to 
determine early seizure outcome
Late seizures: no difference between the  
2 groups
Szaflarski 
et al. (18)
RCT 52 Phenytoin versus levetiracetam
Treatment was started within 24 h of injury between the  
2 groups
Early seizures: no difference between the  
2 groups
Late seizures: study was not designed to 
determine late seizure outcome
Temkin 
et al. (19)
RCT 379 Phenytoin for 1 week versus valproate for 1 month versus 
valproate for 6 months
Treatment was started within 24 h of injury
Follow-up of these groups continued for 2 years
Early seizures: no difference among  
3 groups
Early seizures: no difference among  
3 groups
Manaka (20) RCT 191 Phenobarbital versus no treatment
Treatment was started within 4 weeks post head injury
They received full dose for 2 years and tapered off in third year
Follow-up in 5 years
Early seizures: study was not designed to 
determine early seizure outcome
Late seizures: no difference among  
3 groups
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which result in further complicating the existing damage. The 
main goal of anticonvulsants is to minimize the brain damage by 
preventing early seizures (9).
The other role of anticonvulsants apart from antiseizure activ-
ity is the neuroprotective effect, which has been demonstrated in 
animal models. Phenytoin, which is still considered as an agent 
of choice, has been shown to have neuroprotective properties in 
animal models. Vartanian and colleagues showed that phenytoin 
has been linked with decreased neuronal damage in neonatal 
rats following hypoxia (10). Another study by Tasker and col-
leagues showed similar results in rat hippocampal structures 
(11). Researchers suggested that neuroprotective effects were 
related to a blockage of voltage-dependent sodium channels 
during hypoxia, which decreased the spread of calcium-induced 
neurotoxicity following hypoxic brain injury (10, 11).
Posttraumatic seizures (PTS) are divided into two subgroups, 
early and late PTS. Early seizures occur within the first 7 days after 
brain injury, and late seizures occur after 7 days of injury. These 
definitions are important in terms of management and predicting 
prognosis of PTE (12).
The prospective randomized trials did not show promising 
results of the role anticonvulsants in the management of PTS. 
The randomized clinical trials are summarized in Table  1. No 
significant differences were seen in the treatment versus the non-
treatment groups (13–20). Summary of selected non-randomized 
trials for posttraumatic seizure prevention was shown in Table 2, 
which also did not show a significant difference between groups 
(21–28).
Temkin and colleagues showed that phenytoin was consid-
ered effective in preventing provoked seizures and promising 
at preventing unprovoked seizures. Carbamazepine was 
considered effective in preventing provoked seizures after TBI, 
although its status was considered uncertain in preventing 
unprovoked seizures. Phenobarbital was considered promising 
at preventing provoked seizures and uncertain at preventing 
unprovoked seizures. Finally, the combination of phenytoin and 
phenobarbital was considered promising to prevent provoked 
and unprovoked seizures. It was also shown that provoked 
seizures showed promising results, but for unprovoked seizures, 
no drugs were shown to be effective. AEDs prescribed to prevent 
epileptogenesis should be avoided until clinical trials have found 
a drug for this purpose (29). Similarly, Chang and Lowenstein 
conducted a literature review of the evidence of AED prophy-
laxis in patients with severe TBI in order to guide better practice 
recommendations. Patients given phenytoin prophylaxis com-
pared to controls had a significantly lower risk of early PTS in 
TABLe 2 | Summary of selected non-randomized trials for posttraumatic seizure prevention.
Reference Study design number of patients 
randomized (N)
Methods Outcome
Servit and 
Musil (21)
Non-RCT 167 Treatment group (n = 143) were administered 
phenytoin or phenobarbital
Control group (n = 24) where conventional 
treatment was used
Duration: 2 years
Early seizures: not applicable
Late seizures: 25% in the control group and 2.1%  
in the treatment group
Inaba et al. (22) Prospective 
controlled trial
813 Participants were administered either  
levetiracetam or phenytoin for 7 days
Early seizures: no difference between the 2 groups
Late seizures: not applicable
Kruer et al.  
(23)
Retrospective 
cohort
109 Retrospective review of patients who received 
levetiracetam or phenytoin
Early seizures: no difference between the 2 groups
Late seizures: not applicable
Gabriel and 
Rowe (24)
Cohort 19 Participants were divided based on levetiracetam 
and phenytoin prophylaxis
Follow-up interview conducted to assess seizure 
outcome
Early seizures: no difference between the 2 groups
Late seizures: no difference between the 2 groups
Jones et al. 
(25)
Cohort 27 Phenytoin versus levetiracetam administered 
during first 24 h post severe TBI
Early seizures: no difference between the 2 groups
Late seizures: not applicable
Bhullar et al. 
(26)
Case-control 93 Phenytoin versus no treatment to determine 
occurrence of early seizures
Early seizures: no difference between the 2 groups
Late seizures: not applicable
Formisano 
et al. (27)
Retrospective 
and prospective
137 Anticonvulsants versus no treatment
Study 1: prospective
Study 2: retrospective
Study 1 – No difference between the 2 groups
Study 2 – Late seizures higher in the treated group
Watson et al. 
(28)
Cohort 404 Glucocorticoids administered within 1 day versus 
no glucocorticoids
Early seizures: not applicable
Late seizures: no difference between the 2 groups
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pooled class I studies. There were no significant differences in 
the risk of late PTS patients receiving phenytoin, carbamazepine, 
or valproate prophylaxis versus controls in pooled class I and 
class II studies. In these studies, adverse effects were frequent, 
but mild and serum AED levels were suboptimal. The authors 
concluded that phenytoin prophylaxis is effective in decreasing 
the risk of early PTS in adult patients with severe TBI. However, 
late PTS are not decreased by AED prophylaxis (30). Current 
guidelines issued by the Brain Trauma Foundation and the 
American Academy of Neurology (AAN) for the management of 
severe TBI recommend seizure prophylaxis only for 7 days post 
injury. Phenytoin still remains the desired treatment because it 
has been extensively studied and there is proven evidence of its 
efficacy. The other antiepileptic agents, such as phenobarbital, 
valproate, and carbamazepine, have gone through limited trials 
as compared to phenytoin and their adverse effect profiles and 
pharmacodynamics properties still make phenytoin the desired 
antiepileptic for early prophylaxis of PTS (30).
The new anticonvulsants were favored over the older agents 
because of their unique pharmacokinetic properties, fewer seri-
ous side effects, and fewer drug–drug interactions (31). A second 
generation anticonvulsant that has generated particular interest is 
levetiracetam (23). Jones and colleagues conducted a retrospective 
study, which showed that levetiracetam can be used as an alterna-
tive to phenytoin, but the study was limited due to a small sample 
size (25). Szaflarski and colleagues conducted the first prospective 
randomized comparative trial of intravenous levetiracetam versus 
phenytoin for seizure prophylaxis in the neurointensive care unit 
setting, which showed that levetiracetam can be used as an alter-
native to phenytoin for seizure prophylaxis in the neuroscience 
intensive care setting. This study had limitations, including a small 
sample size and a lack of data reported on the concomitant use of 
sedating agents for induction of pharmacologically-induced coma 
(18). Kirmani and colleagues also conducted a literature review 
on the role of intravenous levetiracetam in seizure prophylaxis 
of severe TBI patients, which showed that levetiracetam can be 
used as an option in acute PTS (32). Gabapentin (GBP) is another 
anticonvulsant that acts at the α2δ-1 submit of the L-type calcium 
channel. It has been shown that chronic administration of GBP 
after cortical injury is antiepileptogenic in the undercut model of 
PTE. The results suggest that it may have a neuroprotective effect 
and may also decrease excitatory synapse formation. These results 
suggest the potential use of GBP as an anticonvulsant following 
TBI (33). A meta-analysis by Zafar and colleagues also concluded 
that there is no particular drug that is superior in preventing early 
seizures (34).
Wroblewski and Joseph reported 10 case studies of TBI 
patients treated with intramuscular midazolam for acute seizure 
cessation after other benzodiazepine drugs had failed. Slight to 
moderate sedation was the only reported side effect. The study 
was limited due to small sample size and was conducted to treat 
rather than prevent PTS (35).
The role of anticonvulsants in early PTS seems favorable as 
compared to late PTS. Anticonvulsants are found to be effective 
in patients who develop PTE.
Phenytoin remains the most commonly used anticonvulsants, 
but the side effects do favor the use of newer anticonvulsants, 
e.g., levetiracetam because of lack of drug–drug interactions and 
availability in parenteral form. The cognitive side effects and 
non linear kinetics limit the use in certain patient populations 
(13). Carbamazepine has shown to be effective but drug–drug 
interactions and unavailability in parenteral form limits the use 
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of this agent. Neurocognitive side effects were also seen in other 
older anticonvulsants, including Phenobarbital, which may mask 
the mental status findings in TBI patients because of the sedating 
effects. Valproate can cause coagulopathy which may result in 
intracranial hemorrhage (30, 31).
Unfortunately, limited scientific data exist, which are specific to 
PTE with other anticonvulsants, and there is a need for additional 
controlled randomized clinical trials to explore more options.
new DiReCTiOnS in THe MAnAGeMenT 
OF POSTTRAUMATiC ePiLePSY
The PTE can be differentiated from PTS that are sequelae from 
TBI. The term PTE signifies recurrent seizure disorder due to TBI 
or any surgery on the brain (36).
Posttraumatic epilepsy remains a challenge despite new medi-
cations that have come in the last decade. We still face problems 
with effective seizure control. TBI is the most common cause of 
acquired focal epilepsy (37–40). The model that was commonly 
used to assess antiepileptogenic interventions is the rostral 
parasagittal fluid percussion injury model (rpFPI) (41–43). This 
model helps in mimicking closed head injury by reproducing 
destructive processes as well as regenerative inflammatory 
processes (44). This is now considered as an excellent model for 
PTE (41–44). This model may progress to intractable multifocal 
epilepsy after a few months post injury (45). Interestingly, this 
model has shown to represent a severe form of PTE which is 
not controlled by carbamazepine, valproic acid, and carisbamate 
(41, 42). One study using this model showed mild cooling of 
epileptogenic focus and prevention of recurrent seizures. Based 
on the above studies, prolonged and mild cooling has been tried 
in these subgroups of patients and was found to be safe and 
improve functional recovery (46–49).
The animal model data also show that it is possible to target 
anti-inflammatory agents that are used for other indications as 
alternative to anticonvulsants. Progesterone has been shown to 
have promising effects in several brain injury models (50). The 
smaller sample size in humans did show some positive results (51, 
52). However, the current evidence is insufficient to support the 
use of progesterone in the management of TBI (53).
COnCLUSiOn
Anticonvulsants have proven to be beneficial in the first 7 days post 
injury. Phenytoin still remains the anticonvulsant of choice because 
it is widely studied and researched as compared to other anticon-
vulsants. Levetiracetam seems to be a viable alternative because of 
its unique pharmacodynamics properties; however, more head-on 
prospective clinical trials are needed regarding phenytoin in order 
to prove its efficacy as a first line agent in PTE. Clinical trials are 
needed to study the efficacy of second and third generation anti-
convulsants in the treatment of PTE. Clinical trials are also needed 
to prove the role of mild selective cooling in patients with PTE.
AUTHOR COnTRiBUTiOnS
All authors listed, have made substantial, direct, and intellectual 
contribution to the work and approved it for publication.
ReFeRenCeS
1. Kovacs SK, Leonessa F, Ling GS. Blast TBI models, neuropathology, and impli-
cations for seizure risk. Front Neurol (2014) 5:47. doi:10.3389/fneur.2014.00047 
2. Krisztian KS, Leonessa F, Grimes J, Ling GSF. A neuropathology approach 
to understanding of explosive blast TBI seizure risk. J Neurol Disord Stroke 
(2014) 2:1071. 
3. Steinmetz S, Tipold A, Löscher W. Epilepsy after head injury in dogs: a natural 
model of post-traumatic epilepsy. Epilepsia (2013) 54(4):580–8. doi:10.1111/
epi.12071 
4. Pitkänen A, McIntosh TK. Animal models of post-traumatic epilepsy. 
J Neurotrauma (2006) 23(2):241–61. doi:10.1089/neu.2006.23.241 
5. Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United 
States: Emergency Department Visits, Hospitalizations, and Deaths. Atlanta, 
GA: Centers for Disease Control and Prevention, National Center for Injury 
Prevention and Control (2010).
6. Annegers JF, Hauser WA, Coan SP, Rocca WA. A population-based study 
of seizures after traumatic brain injuries. N Engl J Med (1998) 338:20–4. 
doi:10.1056/NEJM199801013380104 
7. Raymont V, Salazar AM, Lipsky R, Goldman D, Tasick G, Grafman J. Correlates 
of post-traumatic epilepsy 35 years following combat brain injury. Neurology 
(2010) 75(3):224–9. doi:10.1212/WNL.0b013e3181e8e6d0 
8. Salazar AM, Jabbari B, Vance SC, Grafman J, Amin D, Dillon JD. Epilepsy after 
penetrating head injury. I. Clinical correlates: a report of the Vietnam Head 
Injury Study. Neurology (1985) 35:1406–14. doi:10.1212/WNL.35.10.1406 
9. Schierhout G, Roberts I. Prophylactic antiepileptic agents after head injury: a 
systematic review. Neurol Neurosurg Psychiatry (1998) 64:108–12. doi:10.1136/
jnnp.64.1.108 
10. Vartanian MG, Cordon JJ, Kupina NC, Schielke GP, Posner A, Raser 
KJ, et  al. Phenytoin pretreatment prevents hypoxic-ischemic brain 
damage in neonatal rats. Brain Res Dev Brain Res (1996) 95(2):169–75. 
doi:10.1016/0165-3806(96)00073-9 
11. Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to hypoglyce-
mia-induced neurotoxicity in organotypic hippocampal culture: protection 
by early tetrodotoxin or delayed MK-801. J Neurosci (1992) 12(11):4298–308. 
12. Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, et  al. 
Nonconvulsive electrographic seizures after traumatic brain injury result in 
a delayed, prolonged increase in intracranial pressure and metabolic crisis. 
Crit Care Med (2007) 35:2830–6. doi:10.1097/01.CCM.0000295667.66853.BC 
13. Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral 
effects of phenytoin prophylaxis of posttraumatic seizures. JAMA (1991) 
265(10):1271–7. doi:10.1001/jama.265.10.1271 
14. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. 
A randomized, double-blind study of phenytoin for the prevention of 
post-traumatic seizures. N Engl J Med (1990) 323(8):497–502. doi:10.1056/
NEJM199008233230801 
15. Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of pro-
phylactically administered phenytoin to prevent early posttraumatic seizures. 
J Neurosurg (1983) 58(2):231–5. doi:10.3171/jns.1983.58.2.0236 
16. Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of pro-
phylactically administered phenytoin to prevent late posttraumatic seizures. 
J Neurosurg (1983) 58(2):236–41. doi:10.3171/jns.1983.58.2.0236 
17. McQueen JK, Blackwood DHR, Harris P, Kalbag RM, Johnson AL. Low risk 
of late post-traumatic seizures following severe head injury: implications 
for clinical trials of prophylaxis. J Neurol Neurosurg Psychiatry (1983) 
46(10):899–904. doi:10.1136/jnnp.46.10.899 
18. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, 
single-blinded comparative trial of intravenous levetiracetam versus phenyt-
oin for seizure prophylaxis. Neurocrit Care (2010) 12:165–72. doi:10.1007/
s12028-009-9304-y 
March 2016 | Volume 7 | Article 325
Kirmani et al. Anticonvulsants in Posttraumatic Epilepsy
Frontiers in Neurology | www.frontiersin.org
19. Temkin NR, Dikmen SS, Anderson GD, Wilensky AJ, Holmes MD, Cohen W, 
et al. Valproate therapy for prevention of posttraumatic seizures: a randomized 
trial. J Neurosurg (1999) 91(4):593–600. doi:10.3171/jns.1999.91.4.0593 
20. Manaka S. Cooperative prospective study on posttraumatic epilepsy: risk 
factors and the effect of prophylactic anticonvulsant. Jpn J Psychiatry Neurol 
(1992) 46(2):311–5. 
21. Servit Z, Musil F. Prophylactic treatment of posttraumatic epilepsy: results of 
a long-term follow-up in Czechoslovakia. Epilepsia (1981) 22(3):315–20. doi:
10.1111/j.1528-1157.1981.tb04115.x 
22. Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, et  al.  
A prospective multicenter comparison of levetiracetam versus phenytoin for 
early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg (2013) 
74(3):766–71. doi:10.1097/TA.0b013e3182826e84 
23. Kruer RM, Harris LH, Goodwin H, Kornbluth J, Thomas KP, Slater LA, et al. 
Changing trends in the use of seizure prophylaxis after traumatic brain injury: 
a shift from phenytoin to levetiracetam. J Crit Care (2013) 28(5):.e9–13. 
doi:10.1016/j.jcrc.2012.11.020 
24. Gabriel WM, Rowe AS. Long-term comparison of GOS-E scores in patients 
treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis 
after traumatic brain injury. Ann Pharmacother (2014) 48(11):1440–4. 
doi:10.1177/1060028014549013 
25. Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, et al. 
Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic 
brain injury. Neurosurg Focus (2008) 25:E3. doi:10.3171/FOC.2008.25.10.E3 
26. Bhullar IS, Johnson D, Paul JP, Kerwin AJ, Tepas JJ, Frykberg ER. More harm 
than good: antiseizure prophylaxis after traumatic brain injury does not 
decrease seizure rates but may inhibit functional recovery. J Trauma Acute 
Care Surg (2014) 76(1):54–61. doi:10.1097/TA.0b013e3182aafd15 
27. Formisano R, Barba C, Buzzi MG, Newcomb-Fernandez J, Menniti-Ippolito 
F, Zafonte R, et al. The impact of prophylactic treatment on post-traumatic 
epilepsy after severe traumatic brain injury. Brain Inj (2007) 21(5):499–504. 
doi:10.1080/02699050701310994 
28. Watson NF, Barber JK, Doherty MJ, Miller JW, Temkin NR. Does glucocor-
ticoid administration prevent late seizures after head injury? Epilepsia (2004) 
45(6):690–4. doi:10.1111/j.0013-9580.2004.59403.x 
29. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepi-
leptic drugs: meta-analysis of controlled trials. Epilepsia (2001) 42:515–24. 
doi:10.1046/j.1528-1157.2001.28900.x 
30. Chang BS, Lowenstein DH; Quality Standards Subcommittee of the American 
Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in 
severe traumatic brain injury: report of the Quality Standards Subcommittee 
of the American Academy of Neurology. Neurology (2003) 60:10–6. 
doi:10.1212/01.WNL.0000031432.05543.14 
31. LaRouche SM. A new look at the second generation antiepileptic drugs: a 
decade of experience. Neurologist (2007) 13(13):133–9. doi:10.1097/01.
nrl.0000256353.14257.7c 
32. Kirmani BF, Mungall D, Ling G. Role of intravenous levetiracetam in seizure 
prophylaxis of severe traumatic brain injury patients. Front Neurol (2013) 
4:170. doi:10.3389/fneur.2013.00170 
33. Li H, Graber KD, Jin S, McDonald W, Barres BA, Prince DA. Gabapentin 
decreases epileptiform discharges in a chronic model of neocortical trauma. 
Neurobiol Dis (2012) 48(3):429–38. doi:10.1016/j.nbd.2012.06.019 
34. Zafar SN, Khan AA, Ghauri AA, Shamim MS. Phenytoin versus levetiracetam 
for seizure prophylaxis after brain injury – a meta analysis. BMC Neurol (2012) 
12:30. doi:10.1186/1471-2377-12-30 
35. Wroblewski BA, Joseph AB. The use of intramuscular midazolam for 
acute seizure cessation or behavioral emergencies in patients with 
traumatic brain injury. Clin Neuropharmacol (1992) 15(1):44–9. 
doi:10.1097/00002826-199202000-00006 
36. Hunt RF, Boychuk JA, Smith BN. Neural circuit mechanisms of post-traumatic 
epilepsy. Front Cell Neurosci (2013) 7:89. doi:10.3389/fncel.2013.00089 
37. Agrawal A, Timothy J, Pandit L, Manju M. Post-traumatic epilepsy: an overview. 
Clin Neurol Neurosurg (2006) 108:433–9. doi:10.1016/j.clineuro.2005.09.001 
38. Eftekhar B, Sahraian MA, Nouralishahi B, Khaji A, Vahabi Z, Ghodsi M, 
et  al. Prognostic factors in the persistence of post-traumatic epilepsy after 
penetrating head injuries sustained in war. J Neurosurg (2009) 110(2):319–26. 
doi:10.3171/2008.4.17519 
39. Christensen J. Traumatic brain injury: risks of epilepsy and implications 
for medicolegal assessment. Epilepsia (2012) 53(4):43–7. doi:10.1111/ 
j.1528-1167.2012.03612.x 
40. Frey LC. Epidemiology of post-traumatic epilepsy: a critical review. Epilepsia 
(2003) 44(10):11–7. doi:10.1046/j.1528-1157.44.s10.4.x 
41. Eastman CL, Verley DR, Fender JS, Temkin NR, D’Ambrosio R. ECoG studies 
of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced 
by head injury in the rat. Exp Neurol (2010) 224(2):369–88. doi:10.1016/ 
j.expneurol.2010.04.013 
42. Eastman CL, Verley DR, Fender JS, Stewart TH, Nov E, Curia G, et  al. 
Antiepileptic and antiepileptogenic performance of carisbamate after head 
injury in the rat: blind and randomized studies. J Pharmacol Exp Ther (2011) 
336(3):779–90. doi:10.1124/jpet.110.175133 
43. Thompson HJ, Lifshitz J, Marklund N, Grady MS, Graham DI, Hovda DA, 
et al. Lateral fluid percussion brain injury: a 15-year review and evaluation. 
J Neurotrauma (2005) 22(1):42–75. doi:10.1089/neu.2005.22.42 
44. D’Ambrosio R, Eastman CL, Darvas F, Fender JS, Verley DR, Farin FM, et al. 
Mild passive focal cooling prevents epileptic seizures after head injury in rats. 
Ann Neurol (2013) 73(2):199–209. doi:10.1002/ana.23764 
45. D’Ambrosio R, Fender JS, Fairbanks JP, Simon EA, Born DE, Doyle DL, et al. 
Progression from frontal-parietal to mesial-temporal epilepsy after fluid 
percussion injury in the rat. Brain (2005) 128(Pt. 1):174–88. doi:10.1093/
brain/awh337 
46. Fox JL, Vu EN, Doyle-Waters M, Brubacher JR, Abu-Laban R, Hu Z. 
Prophylactic hypothermia for traumatic brain injury: a quantitative systematic 
review. CJEM (2010) 12:355–64. 
47. Polderman KH. Induced hypothermia and fever control for prevention 
and treatment of neurological injuries. Lancet (2008) 371(9628):1955–69. 
doi:10.1016/S0140-6736(08)60837-5 
48. Jiang JY, Xu W, Li WP, Gao GY, Bao YH, Liang YM, et  al. Effect of long-
term mild hypothermia or short-term mild hypothermia on outcome of 
patients with severe traumatic brain injury. J Cereb Blood Flow Metab (2006) 
26(6):771–6. doi:10.1038/sj.jcbfm.9600253 
49. Sadaka F, Veremakis C. Therapeutic hypothermia for the management of 
intracranial hypertension in severe traumatic brain injury: a systematic 
review. Brain Inj (2012) 26(7–8):899–908. doi:10.3109/02699052.2012.661120 
50. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in traumatic 
and ischemic brain injury. Prog Brain Res (2009) 175:219–37. doi:10.1016/
S0079-6123(09)17515-5 
51. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein 
FC, et  al. ProTECT: a randomized clinical trial of progesterone for acute 
traumatic brain injury. Ann Emerg Med (2007) 49(4):391–402. doi:10.1016/j.
annemergmed.2006.07.932 
52. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the adminis-
tration of progesterone for patients with acute severe traumatic brain injury: a 
randomized controlled trial. Crit Care (2008) 12(2):R61. doi:10.1186/cc6887 
53. Stein DG, Sayeed I. Is progesterone worth consideration as a treatment for 
brain injury? Am J Roentgenol (2010) 194(1):20–2. doi:10.2214/AJR.09.3407 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Kirmani, Robinson, Fonkem, Graf and Huang. This is an open-ac-
cess article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
